We provide you with 20 years of free, institutional-grade data for GRAY stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GRAY. Explore the full financial landscape of GRAY stock.
| Reported Date | CIK | Ticker | Type |
|---|
Graybug Vision, Inc(NASDAQ:GRAY) 
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb...
Website: http://www.graybug.com
Founded: 2011
Full Time Employees: 32 (May 2021)
CEO: Frédéric Guerard
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about GRAY stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.